M P Sajan1, R V Farese. 1. Medical and Research Services, James A Haley Veterans Medical Center, 13000 Bruce B Downs Blvd, Tampa, FL 33612, USA.
Abstract
AIMS/HYPOTHESIS: We examined the role of protein kinase C-ι (PKC-ι) in mediating alterations in the abundance of enzymes in hepatocytes of type 2 diabetic humans that contribute importantly to the development of lipid and carbohydrate abnormalities in type 2 diabetes. METHODS: We examined (1) insulin signalling in isolated hepatocytes of non-diabetic and type 2 diabetic humans and (2) the effects of two newly developed small molecule PKC-ι inhibitors on aberrant signalling and downstream processes. RESULTS: In contrast with PKC-ι deficiency in diabetic muscle, which diminishes glucose transport, PKC-ι in diabetic hepatocytes was overproduced and overactive, basally and after insulin treatment, and, moreover, was accompanied by increased abundance of PKC-ι-dependent lipogenic, proinflammatory and gluconeogenic enzymes. Heightened PKC-ι activity most likely reflected heightened activity of IRS-2-dependent phosphatidylinositol 3-kinase (PI3K), as IRS-1 levels and IRS-1/PI3K activity were markedly diminished. Importantly, insulin-stimulated PKC-ι abundance and its overabundance in diabetic hepatocytes was reversed in vitro by both insulin deprivation and PKC-ι inhibitors; this suggested operation of an insulin-driven, feed-forward/positive-feedback mechanism. In contrast with PKC-ι, protein kinase B (Akt2) activity and activation by insulin was diminished, apparently reflecting IRS-1 deficiency. Treatment of diabetic hepatocytes with PKC-ι/λ inhibitors diminished abundance of lipogenic, proinflammatory and gluconeogenic enzymes. CONCLUSIONS/ INTERPRETATION: Our findings suggest that a vicious cycle of PKC-ι overactivity and overproduction exists in hepatocytes of humans with type 2 diabetes and contributes importantly to maintaining overactivity of lipogenic, proinflammatory and gluconeogenic pathways, which underlies the lipid and carbohydrate abnormalities in type 2 diabetes.
AIMS/HYPOTHESIS: We examined the role of protein kinase C-ι (PKC-ι) in mediating alterations in the abundance of enzymes in hepatocytes of type 2 diabetichumans that contribute importantly to the development of lipid and carbohydrate abnormalities in type 2 diabetes. METHODS: We examined (1) insulin signalling in isolated hepatocytes of non-diabetic and type 2 diabetichumans and (2) the effects of two newly developed small molecule PKC-ι inhibitors on aberrant signalling and downstream processes. RESULTS: In contrast with PKC-ι deficiency in diabetic muscle, which diminishes glucose transport, PKC-ι in diabetic hepatocytes was overproduced and overactive, basally and after insulin treatment, and, moreover, was accompanied by increased abundance of PKC-ι-dependent lipogenic, proinflammatory and gluconeogenic enzymes. Heightened PKC-ι activity most likely reflected heightened activity of IRS-2-dependent phosphatidylinositol 3-kinase (PI3K), as IRS-1 levels and IRS-1/PI3K activity were markedly diminished. Importantly, insulin-stimulated PKC-ι abundance and its overabundance in diabetic hepatocytes was reversed in vitro by both insulin deprivation and PKC-ι inhibitors; this suggested operation of an insulin-driven, feed-forward/positive-feedback mechanism. In contrast with PKC-ι, protein kinase B (Akt2) activity and activation by insulin was diminished, apparently reflecting IRS-1 deficiency. Treatment of diabetic hepatocytes with PKC-ι/λ inhibitors diminished abundance of lipogenic, proinflammatory and gluconeogenic enzymes. CONCLUSIONS/ INTERPRETATION: Our findings suggest that a vicious cycle of PKC-ι overactivity and overproduction exists in hepatocytes of humans with type 2 diabetes and contributes importantly to maintaining overactivity of lipogenic, proinflammatory and gluconeogenic pathways, which underlies the lipid and carbohydrate abnormalities in type 2 diabetes.
Authors: Melody Stallings-Mann; Lee Jamieson; Roderick P Regala; Capella Weems; Nicole R Murray; Alan P Fields Journal: Cancer Res Date: 2006-02-01 Impact factor: 12.701
Authors: K Ueki; T Yamauchi; H Tamemoto; K Tobe; R Yamamoto-Honda; Y Kaburagi; Y Akanuma; Y Yazaki; S Aizawa; R Nagai; T Kadowaki Journal: J Clin Invest Date: 2000-05 Impact factor: 14.808
Authors: Mary Beeson; Mini P Sajan; Michelle Dizon; Dmitry Grebenev; Joaquin Gomez-Daspet; Atsushi Miura; Yoshinori Kanoh; Jennifer Powe; Gautam Bandyopadhyay; Mary L Standaert; Robert V Farese Journal: Diabetes Date: 2003-08 Impact factor: 9.461
Authors: Mary L Standaert; Mini P Sajan; Atsushi Miura; Yoshinori Kanoh; Hubert C Chen; Robert V Farese; Robert V Farese Journal: J Biol Chem Date: 2004-04-06 Impact factor: 5.157
Authors: Mini P Sajan; Barbara C Hansen; Margaret G Higgs; C Ron Kahn; Ursula Braun; Michael Leitges; Collin R Park; David M Diamond; Robert V Farese Journal: Neurobiol Aging Date: 2017-09-15 Impact factor: 4.673
Authors: Mini P Sajan; Robert A Ivey; Mackenzie Lee; Stephen Mastorides; Michael J Jurczak; Varman T Samuels; Gerald I Shulman; Ursula Braun; Michael Leitges; Robert V Farese Journal: Mol Endocrinol Date: 2014-05-30
Authors: Irene S Tobias; Manuel Kaulich; Peter K Kim; Nitya Simon; Estela Jacinto; Steven F Dowdy; Charles C King; Alexandra C Newton Journal: Biochem J Date: 2015-12-03 Impact factor: 3.857